Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 9/20 | 0.33 |
| ▸ | KIT | P10721 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359016 | 1.00 | S1PR3 (0.34) | S1PR3PDPK1BDKRB1KITJAK2 | |
| SCHEMBL31359052 | 0.89 | KIT (0.33) | S1PR3PDPK1BDKRB1KITOPRM1 | |
| SCHEMBL31358994 | 0.89 | KIT (0.33) | S1PR3PDPK1BDKRB1KITOPRM1 | |
| SCHEMBL31359019 | 0.81 | PDPK1 (0.36) | S1PR3PDPK1KITJAK2JAK3 | |
| SCHEMBL31161003 | 0.81 | PDPK1 (0.36) | S1PR3PDPK1KITJAK2JAK3 | |
| SCHEMBL31145998 | 0.75 | S1PR3 (0.35) | S1PR3PDPK1BDKRB1KITJAK2 | |
| SCHEMBL31145937 | 0.75 | S1PR3 (0.35) | S1PR3PDPK1BDKRB1KITJAK2 | |
| SCHEMBL31359114 | 0.75 | ITGB1 (0.36) | S1PR3PDPK1KITJAK2JAK3 | |
| SCHEMBL31359030 | 0.75 | ITGB1 (0.36) | S1PR3PDPK1KITJAK2JAK3 | |
| SCHEMBL31146188 | 0.74 | S1PR3 (0.36) | S1PR3PDPK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | S1PR3 4520/4885PDPK1 505/4885BDKRB1 1015/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | S1PR3 3322/4885PDPK1 2973/4885BDKRB1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.